SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 22, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced that data published today in the Journal of the National Cancer Institute demonstrate that the company’s Decipher Prostate Genomic Classifier may help identify African American men with early,
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 13, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that John Leite , Ph.D., has joined the company as senior vice president and general manager of Pulmonology & Market Access. Dr. Leite’s responsibilities will include leading commercial
Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer Data support Veracyte’s plan to expand test availability in the U.S.
Findings presented at the European Respiratory Society International Congress 2022 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 7, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 1, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a fireside chat at the Morgan Stanley 20 th Annual Global Healthcare
New data support continued expansion of the company’s tests, including determining treatment prognosis in men with advanced prostate cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 31, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company’s
Findings suggest Veracyte’s immuno-oncology biomarkers could help predict response to therapy, improve patient outcomes and guide immunotherapy clinical trials SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 29, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced that new data published today in
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 11, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced the appointment of Eliav Barr , M.D., to its board of directors, effective immediately. “We are thrilled to welcome Eliav Barr to our board,” said Marc Stapley , Veracyte’s chief executive
Grew Total Revenue to $72.9 million , an Increase of 32% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 2, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2022 .
The Genomic Test Demonstrated 100 Percent Sensitivity and 100 Percent Specificity for MTC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 20, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in Thyroid show that the company’s RNA
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
